Learn more about whether Intra-Cellular Therapies, Inc. or Jazz Pharmaceuticals plc is a better investment based on AAII's A+ ...

The AdventHealth Neuroscience Institute is testing IDP-023 for primary or nonactive secondary progressive multiple sclerosis ...

Target enrollment exceeded with 1009 patients randomized in the main cohort and 410 patients in the exploratory cohort ...

Winrevair (sotatercept-csrk), compared to placebo, reduced the risk of all-cause death, lung transplantation, and hospitalization.

ZOLAR is a first-in-human, proof-of-concept and biodistribution trial that uses positron emission tomography (PET) to ...

A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.

Here is a roundup of March 2025 U.S. FDA approvals across cancer subtypes, including prostate, bladder and gastrointestinal ...

AstraZeneca and the Memorial Sloan Kettering Cancer Center (MSK) have tapped digital health tech company IgniteData to ...

Takeda boosts profit margins with AI-driven growth, FY2024 guidance upgrade, share buyback plan & promising drug launches.

Intrathecal treatment with a vector-based gene therapy was associated with a greater improvement in motor function at 52 ...

Learn more about whether Corcept Therapeutics Incorporated or Intra-Cellular Therapies, Inc. is a better investment based on ...

In light of these findings, Axsome has announced plans to initiate a Phase 3 trial focusing exclusively on MDD patients with EDS in 2025. This decision comes after observing clinically meaningful and ...